Literature DB >> 11916611

Graves' ophthalmopathy: a preventable disease?

Luigi Bartalena1, Claudio Marcocci, Aldo Pinchera.   

Abstract

Most patients with Graves' disease have some degree of ocular involvement, but only 3-5% of them develop severe ophthalmopathy (1). The reasons why only such a minority of patients with Graves' disease have severe expression of the ophthalmopathy remain to be elucidated. One possible explanation is that non-severe ophthalmopathy and severe ophthalmopathy are two different disorders with different genetic backgrounds; alternatively, they might be part of a spectrum of different conditions ranging from absent ocular involvement to most severe ophthalmopathy. In this case, external variables (i.e. environmental factors) must contribute to the nature of the expression of the disease. How important are they? How far can our intervention on environmental factors go towards reducing the risk of progression of the ophthalmopathy? In other words, to which extent, if any, is Graves' ophthalmopathy preventable? The aim of this mini-review is to address the above issues.

Entities:  

Mesh:

Year:  2002        PMID: 11916611     DOI: 10.1530/eje.0.1460457

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  19 in total

Review 1.  Relationship between cigarette smoking and Graves' ophthalmopathy.

Authors:  L Hegediüs; T H Brix; P Vestergaard
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

2.  Graves' ophthalmopathy: search for shared autoantigen(s) continues.

Authors:  L Bartalena
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

Review 3.  An update on medical management of Graves' ophthalmopathy.

Authors:  L Bartalena; C Marcocci; M L Tanda; E Piantanida; A Lai; M Marinò; A Pinchera
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

4.  Greater Efficacy of Total Thyroidectomy versus Radioiodine Therapy on Hyperthyroidism and Thyroid-Stimulating Immunoglobulin Levels in Patients with Graves' Disease Previously Treated with Antithyroid Drugs.

Authors:  Shakeel Kautbally; Orsalia Alexopoulou; Chantal Daumerie; François Jamar; Michel Mourad; Dominique Maiter
Journal:  Eur Thyroid J       Date:  2012-06-20

Review 5.  Graves' orbitopathy: imperfect treatments for a rare disease.

Authors:  Luigi Bartalena
Journal:  Eur Thyroid J       Date:  2013-11-20

Review 6.  Immunopathogenesis of thyroid eye disease: emerging paradigms.

Authors:  Vibhavari M Naik; Milind N Naik; Robert A Goldberg; Terry J Smith; Raymond S Douglas
Journal:  Surv Ophthalmol       Date:  2010 May-Jun       Impact factor: 6.048

7.  [Driving competency after combined treatment with methylprednisolone and orbital radiotherapy for endocrine orbitopathy].

Authors:  I Sterker; H Tegetmeyer; K Papsdorf; D Führer
Journal:  Ophthalmologe       Date:  2010-10       Impact factor: 1.059

Review 8.  Management of thyroid disorders.

Authors:  L D K E Premawardhana; J H Lazarus
Journal:  Postgrad Med J       Date:  2006-09       Impact factor: 2.401

Review 9.  Prevalence and natural history of Graves' orbitopathy in the XXI century.

Authors:  E Piantanida; M L Tanda; A Lai; L Sassi; L Bartalena
Journal:  J Endocrinol Invest       Date:  2013-04-16       Impact factor: 4.256

10.  Risk factors associated with the severity of thyroid-associated orbitopathy in Korean patients.

Authors:  Ji Hwan Lee; Sang Yeul Lee; Jin Sook Yoon
Journal:  Korean J Ophthalmol       Date:  2010-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.